Key Insights• According to the research report, "Argentina Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the Argentina Point of Care Diagnostics Market is anticipated to grow at more than 8.05% CAGR from 2026 to 2031.• The primary driver behind Argentina’s Point-of-Care (POC) diagnostics adoption is the need for cost-effective, decentralized medical solutions amid macro-economic fluctuations and currency pressures. To reduce operational expenses associated with centralized reference laboratories and imported bulk diagnostic reagents, Argentina's public health networks (Sistema Nacional de Salud) and private pre-paid medicine networks (Medicina Prepaga) are deploying portable benchtop analyzers and rapid test kits across primary care centers (Centros de Atención Primaria de la Salud - CAPS).• Argentina’s varying regional climates ranging from tropical northern provinces to urban centers like Buenos Aires create significant public health vulnerabilities to vector-borne endemic arboviruses (specifically Dengue, Chikungunya, and Chagas disease). Traditional central laboratory workflows often faced multi-day turnaround delays during seasonal outbreaks. A key technological breakthrough transforming regional disease surveillance is the deployment of portable, automated isothermal nucleic acid amplification (LAMP) platforms and rapid multiplex PCR units.• Point-of-care testing in Argentina is transitioning from standalone lateral flow strips toward connected, digital diagnostic nodes linked to health information systems. Under federal digital health policies and provincial electronic medical record initiatives (Historia Clínica Electrónica - HCE), modern POCT hardware deployed across clinics, urgent care units, and home health services features integrated Bluetooth and mobile connectivity.Market Outlook• As public health authorities prioritize preventive screening to avoid costly tertiary hospital admissions, municipal and provincial budgets are directing increased resources toward decentralized screening tools for metabolic, cardiovascular, and infectious conditions. Concurrently, retail pharmacies and independent clinical laboratories are expanding point-of-care diagnostic services for walk-in patients, creating a dual-track market structure that balances public health tenders with out-of-pocket self-testing demand.• Key international commercial developers and local suppliers serving the Argentine market include Abbott Laboratories, F.

Hoffmann-La Roche Ltd., Siemens Healthineers, Danaher Corporation, bioMérieux, Wiener Lab Group, and Laboratorios Britania, operating under sanitary registration and medical device clearance frameworks enforced by ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) and supported by professional guidance from the Ministerio de Salud de la Nación and the Confederación Unificada Bioquímica de la República Argentina (CUBRA).Market DynamicsDriver: Rising prevalence of chronic and infectious diseases requiring decentralized careArgentina faces a growing health burden from chronic conditions (such as diabetes and cardiovascular ailments) alongside recurring regional infectious disease pressures. This creates an ongoing clinical necessity for decentralized point-of-care (POC) diagnostics that allow rapid testing, immediate triage, and efficient tracking in local clinics and regional medical centers without waiting on over-burdened central laboratories.Challenge: Macroeconomic volatility and import/currency restraintsNavigating Argentina’s economic climate introduces significant financial and logistical challenges for medical device distribution. Currency fluctuations, high inflation rates, and evolving import protocols complicate long-term capital investments, pricing consistency, and supply chain continuity for foreign diagnostic manufacturers.Trend: Regulatory modernization and digital administrative streamliningArgentina's national health regulatory authority (ANMAT) has implemented modernizing measures and digital frameworks (such as electronic submission portals and streamlined pathways) to reduce administrative barriers, accelerate product notification, and align local evaluation standards more closely with international frameworks.Segment Analysis Argentina Point of Care Diagnostics By Product• Glucose monitoring kits in Argentina are increasingly positioned as part of continuous diabetes self-management rather than simply as standalone meters. Product differentiation centers on small-volume capillary sampling, easier strip insertion, automatic result storage, connectivity with mobile applications, and simplified interfaces for repeated home use. Argentina's ANMAT framework distinguishes professional-use IVDs from self-evaluation products and requires the authorized conditions of use to be identified, making the intended user an important part of product design and commercialization.• Infectious-disease POC kits in Argentina encompass rapid antigen and antibody tests as well as molecular platforms designed to identify pathogens closer to the point of care. Their distinctive role is to shorten the pathway from specimen collection to actionable clinical information, particularly where centralized laboratory processing is less immediate.

Argentina's framework places strong emphasis on intended use and intrinsic risk, with ANMAT requiring IVDs to be classified into risk groups and to satisfy applicable safety and performance requirements.• Pregnancy and fertility kits are naturally compatible with decentralized testing because urine-based testing can be performed privately without an initial laboratory visit. The segment extends beyond conventional pregnancy strips into ovulation and fertility-window testing, with digital readers increasingly helping users interpret results and track repeated measurements. Argentina explicitly recognizes self-evaluation IVD products as products used by the patient according to the manufacturer's instructions, without providing a conclusive diagnosis on their own.• Hematology POC kits bring selected blood measurements closer to the clinical encounter through portable analyzers, cartridges, and simplified specimen workflows. Applications can include hemoglobin, coagulation-related parameters, and other blood measurements that complement conventional laboratory testing. In Argentina, the regulatory framework covers both IVD reagents and associated diagnostic instruments, while classification is based on the intrinsic risk to patients, users, operators, or third parties.• Cardiometabolic monitoring kits in Argentina increasingly combine glucose, cholesterol, coagulation, and related measurements with digital disease-management workflows. Connected meters can transform individual readings into longitudinal records that can be reviewed by patients or incorporated into professional care pathways.

The regulatory environment is relevant because ANMAT distinguishes professional-use products from self-evaluation devices and separately recognizes devices intended for patient self-collection of specimens that are subsequently analyzed by a laboratory.• Urinalysis kits are particularly suitable for decentralized testing because urine collection is non-invasive and multi-parameter strips can provide preliminary information with minimal equipment. The segment includes traditional visually interpreted dipsticks as well as reader-assisted systems that standardize interpretation and electronically record findings. In Argentina, their role can extend from immediate professional screening to broader decentralized workflows, while the regulatory status depends on intended use and risk classification.• Cholesterol test strips connect conventional lipid testing with near-patient cardiometabolic screening by enabling measurements from small blood specimens using compact readers. Product development is increasingly focused on simpler capillary sampling, rapid processing, automated interpretation, and digital recording of results rather than the disposable strip alone. Argentina's risk-based IVD system requires the intended purpose and intrinsic risk of the product to be considered for classification, while self-evaluation products have a defined regulatory meaning.• Other Products include cardiac biomarkers, inflammatory markers, electrolytes, blood gases, coagulation assays, toxicology, reproductive biomarkers, and multi-analyte systems. These products are increasingly built around compact analyzers and cartridge-based architectures that can combine several laboratory functions within one platform.

Argentina's regulatory framework is broad enough to cover IVD instruments, reagents, and integrated systems, while the classification rules can be updated in response to technological progress and information from incidents associated with IVD use. Argentina Point of Care Diagnostics By Technology/Platform• Lateral flow assays remain well suited to Argentina's decentralized diagnostics environment because they combine portability, rapid operation, and limited equipment requirements. They support applications ranging from pregnancy and fertility testing to infectious-disease screening, with the regulatory pathway influenced by intended user and clinical purpose. Argentina's ANMAT framework explicitly distinguishes professional-use IVDs from self-evaluation products, meaning that the same basic lateral-flow architecture can have different regulatory considerations depending on whether it is intended for trained personnel or patient use.• PCR and isothermal nucleic-acid amplification platforms are bringing molecular pathogen detection closer to the patient through compact analyzers and integrated cartridges. These systems can combine sample preparation, amplification, and detection within a controlled workflow, reducing the number of manual laboratory steps. Argentina's risk-based IVD classification framework is particularly relevant to molecular infectious-disease systems because the regulatory group depends on intrinsic risk and intended purpose.• Microfluidics and immunoassays allow laboratory processes to be compressed into small cartridges and portable instruments. Microfluidic systems can manipulate tiny sample volumes while integrating preparation, reaction, separation, and detection, whereas immunoassays enable measurement of proteins, hormones, antigens, antibodies, and other biomarkers.

In Argentina, these platforms are relevant to POC systems attempting to reproduce selected laboratory capabilities outside conventional laboratories.• Dipsticks and test strips remain among the most accessible POC formats in Argentina because they require little instrumentation and can be used directly at the testing site. Applications include urinalysis, glucose monitoring, pregnancy and fertility testing, and selected cardiometabolic assessments. Reader-assisted formats increasingly add automated interpretation and digital data capture, turning a basic disposable strip into part of a more standardized diagnostic workflow. Argentina Point of Care Diagnostics By End-User• Argentine hospitals and critical-care centers can use POC diagnostics when rapid measurements complement centralized laboratory testing during acute clinical situations. Emergency departments, intensive-care units, operating environments, and other high-dependency areas can benefit from testing performed close to the patient, reducing dependence on conventional specimen-transport workflows. Argentina's regulatory structure distinguishes professional-use IVDs from patient self-evaluation and self-collection products, reinforcing the professional nature of hospital POC workflows.• Clinical and diagnostic laboratories serve as an important quality-management backbone for decentralized testing in Argentina. Their role can include method verification, quality control, calibration, operator training, troubleshooting, review of unusual results, and confirmation testing where required.

POC therefore complements rather than necessarily replaces centralized laboratory services. ANMAT maintains specific regulatory structures for IVD products, including registration, modifications, renewals, and transfers, while the national framework incorporates MERCOSUR essential safety and performance requirements.• Home care and self-testing represent the consumer-facing side of Argentina's POC diagnostics ecosystem, particularly for glucose, pregnancy, fertility, cholesterol, and selected other applications. Argentina's ANMAT regulations specifically define self-evaluation products as IVDs intended for use by patients based on the manufacturer's instructions and distinguish them from self-collection products, in which the patient collects a specimen that is subsequently analyzed by a laboratory. This distinction creates different decentralized pathways: direct home testing versus home collection followed by professional analysis.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Point of Care Diagnostics Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Glucose Monitoring Kits• Infectious Diseases Testing Kits• Pregnancy And Fertility Testing Kits• Hematology Testing Kits• Cardiometabolic Monitoring Kits• Urinalysis Testing Kits• Cholesterol Test Strips• Other ProductsBy Technology/Platform• Lateral Flow Assays• Molecular Diagnostics (PCR/INAAT)• Microfluidics & Immunoassays• Dipsticks & Test StripsBy End-User• Hospitals & Critical Care Centers• Clinical & Diagnostic Laboratories• Home Care & Self-TestingBy Mode Of Purchase• Prescription Based Products• OTC ProductsBy Sample• Blood• Urine• Nasal and Oropharyngeal Swabs.